PTAFR and melanoma: Immunochemistry assays on tumors from mice injected with apoptotic cells and a sub-tumorigenic dose of melanoma cells showed that treatment with the PAFR antagonist reduced neutrophil infiltration in the first 24 h of tumor injection and after three days, infiltration of macrophages.